Literature DB >> 31512019

Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study.

Maia Kayal1, Aparna Saha2, Priti Poojary2, Sudarshan Paramsothy3, Robert Hirten3, Louis Cohen3, Zane Gallinger3, Saurabh Mehandru3, Judy Cho3, Alexander Greenstein4, Girish Nadkarni2, Marla C Dubinsky3, Jean-Frederic Colombel3, Benjamin Cohen3, Ryan Ungaro3.   

Abstract

PURPOSE: Despite advances in biologic therapy, approximately 10-15% of ulcerative colitis (UC) patients require surgery. We aimed to (1) examine the rates of emergent colectomy and elective ileal pouch anal anastomosis (IPAA) over time among UC patients in the USA and (2) investigate disparities in surgery rates by patient demographics.
METHODS: Data from the Nationwide Inpatient Sample (NIS) from 2000 to 2014 were analyzed. Inclusion criteria were admissions with a primary UC ICD-9-CM diagnosis code and age > 18. Emergent cases were defined as those admitted through the emergency room with an outcome ICD-9-CM code for subtotal colectomy. Elective IPAA cases were defined with an outcome ICD-9-CM code for IPAA, used as a surrogate measure of colectomy. Patient and hospital-level demographics were analyzed. Temporal trends of colectomy were analyzed utilizing joinpoint-regression analysis with calculation of annual percentage change (APC).
RESULTS: A total of 470,708 admissions were included over the 14-year period. Emergent colectomy rate significantly declined (APC - 7.35%, p = 0.0002), while the rate of elective IPAA remained stable (APC - 0.21%, p = 0.8). Emergent colectomy rates declined similarly across all demographics, though not as marked among patients age 50 and older and Medicare patients. Elective IPAA rates were significantly lower among blacks and patients with public insurance.
CONCLUSIONS: There has been a significant decline in emergent UC colectomy rates in the USA; however, the overall need for surgery appears unchanged given stable IPAA rates. This suggests a limited impact on overall surgery rates with a shift from emergent to elective procedures.

Entities:  

Keywords:  Colectomy; Disparities; Ileal pouch anal anastomosis; Minority; Ulcerative colitis

Mesh:

Year:  2019        PMID: 31512019      PMCID: PMC7060938          DOI: 10.1007/s00384-019-03375-2

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  28 in total

1.  Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort.

Authors:  Geoffrey C Nguyen; Esther A Torres; Miguel Regueiro; Gillian Bromfield; Alain Bitton; Joanne Stempak; Themistocles Dassopoulos; Philip Schumm; Federico J Gregory; Anne M Griffiths; Stephen B Hanauer; Jennifer Hanson; Mary L Harris; Sunanda V Kane; Heather Kiraly Orkwis; Raymond Lahaie; Maria Oliva-Hemker; Pierre Pare; Gary E Wild; John D Rioux; Huiying Yang; Richard H Duerr; Judy H Cho; A Hillary Steinhart; Steven R Brant; Mark S Silverberg
Journal:  Am J Gastroenterol       Date:  2006-05       Impact factor: 10.864

2.  Racial and ethnic differences in health care utilization and outcomes among ulcerative colitis patients in an integrated health-care organization.

Authors:  Dan Li; Bernadette Collins; Fernando S Velayos; Liyan Liu; James D Lewis; James E Allison; Nicole T Flowers; Susan Hutfless; Oren Abramson; Lisa J Herrinton
Journal:  Dig Dis Sci       Date:  2013-10-31       Impact factor: 3.199

3.  Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital.

Authors:  M Anthony Sofia; David T Rubin; Ningqi Hou; Joel Pekow
Journal:  Dig Dis Sci       Date:  2014-04-22       Impact factor: 3.199

4.  Market share and costs of biologic therapies for inflammatory bowel disease in the USA.

Authors:  H Yu; D MacIsaac; J J Wong; Z M Sellers; A A Wren; R Bensen; C Kin; K T Park
Journal:  Aliment Pharmacol Ther       Date:  2017-11-22       Impact factor: 8.171

5.  As Infliximab Use for Ulcerative Colitis Has Increased, so Has the Rate of Surgical Resection.

Authors:  Cindy Kin; M Kate Bundorf
Journal:  J Gastrointest Surg       Date:  2017-05-08       Impact factor: 3.452

6.  Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada.

Authors:  Sarah E Moore; Kimberlyn M McGrail; Sandra Peterson; Manoj J Raval; Ahmer A Karimuddin; P Terry Phang; Brian Bressler; Carl J Brown
Journal:  Dis Colon Rectum       Date:  2014-01       Impact factor: 4.585

7.  Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study.

Authors:  Priti Poojary; Aparna Saha; Kinsuk Chauhan; Priya Simoes; Bruce E Sands; Judy Cho; Thomas Ullman; Girish Nadkarni; Ryan Ungaro
Journal:  Inflamm Bowel Dis       Date:  2017-03       Impact factor: 5.325

8.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

Authors:  Gunnar Järnerot; Erik Hertervig; Ingalill Friis-Liby; Lars Blomquist; Per Karlén; Christer Grännö; Mogens Vilien; Magnus Ström; Ake Danielsson; Hans Verbaan; Per M Hellström; Anders Magnuson; Bengt Curman
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

9.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.

Authors:  William J Sandborn; Paul Rutgeerts; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Jiandong Lu; Kevin Horgan; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  Gastroenterology       Date:  2009-07-28       Impact factor: 22.682

10.  The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study.

Authors:  K M Reich; H-J Chang; A Rezaie; H Wang; K J Goodman; G G Kaplan; L W Svenson; G Lees; R N Fedorak; K I Kroeker
Journal:  Aliment Pharmacol Ther       Date:  2014-07-13       Impact factor: 8.171

View more
  4 in total

1.  Effects of ethnicity and socioeconomic status on surgical outcomes from inflammatory bowel disease.

Authors:  Dimitrios Stamatiou; David N Naumann; Helen Foss; Rishi Singhal; Sharad Karandikar
Journal:  Int J Colorectal Dis       Date:  2022-05-13       Impact factor: 2.571

2.  Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix.

Authors:  Ohad Atia; Gemma Pujol-Muncunill; Víctor Manuel Navas-López; Esther Orlanski-Meyer; Oren Ledder; Raffi Lev-Tzion; Gili Focht; Eyal Shteyer; Ronen Stein; Marina Aloi; Richard K Russell; Javier Martin-de-Carpi; Dan Turner
Journal:  Aliment Pharmacol Ther       Date:  2022-06-23       Impact factor: 9.524

3.  Trends in Morbidity and Mortality Following Colectomy Among Patients with Ulcerative Colitis in the Biologic Era (2002-2013): A Study Using the National Inpatient Sample.

Authors:  Babatunde Olaiya; Benjamin D Renelus; Mikolaj Filon; Sumona Saha
Journal:  Dig Dis Sci       Date:  2020-07-16       Impact factor: 3.199

Review 4.  Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts.

Authors:  Lester Tsai; Christopher Ma; Parambir S Dulai; Larry J Prokop; Samuel Eisenstein; Sonia L Ramamoorthy; Brian G Feagan; Vipul Jairath; William J Sandborn; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-27       Impact factor: 13.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.